I am pleased to inform you that the primary result of JCOG1109 was published in the Lancet today. The neoadjuvant triplet chemotherapy would be the standard care for the locally advanced ESCC. Many thanks to everyone involved. thelancet.com/action/showPdf…

Among individuals with a CDH1 gene variant, the risk of gastric cancer was lower than previously described, while risk of female breast cancer was similar to previous estimates. ja.ma/4enFwMc

Exciting news: The LBA titles of the ESMO #GastrointestinalCancers Congress 2024 are now online. Don't miss out on the latest research in these sessions: 📅Proffered Paper session: 27 June ow.ly/OpZm50SiEXW 📅Mini Oral session 2: 28 June ow.ly/X7vZ50SiEXV #ESMOGI24

LGBTQ+ cancer survivors—especially transgender and gender nonconforming individuals—have higher odds of chronic health conditions compared to straight and cisgender survivors, according to a study published in Cancer Epidemiology, Biomarkers & Prevention: bit.ly/4bgpP6L @austinh2o_ @uncpublichealth

POLE-altered colorectal tumors are exquisitely sensitive to immunotherapy. Filippo Pietrantonio and team have put together one of the largest datasets to describe this unique subtype. Michael Cecchini and I put the study in context here: sciencedirect.com/science/articl… Annals of Oncology

🔥 The bottom line for ICI+perioperative chemo in gastric cancer🔥 ESMO - Eur. Oncology #ESMOGI24 Plenary ➡️ KN585 a negative trial but long term benefit in PDL1 high/MSI subgroups MATTERHORN incoming....will better chemo partner + statistical design carry it through? 🤔 #ESMOAmbassadors

Biomarker based results of the academic italian ARMANI trial guided by INT GI oncology and presented by a splendid Giovanni Randon ESMO - Eur. Oncology #ESMOGI2024

Giovanni is an amazing human being and doctor! Thank you!!Well deserved💓💓

That’s a wrap! Wonderful people and science and the time to have a more relaxed meeting is a plus point!! ESMO - Eur. Oncology #ESMOGI24 Sara Lonardi

Last satuday #ESMOGI24

Are 🫵🏻 ready to shine some light on the value of PD-L1 in #GastricCancer? 👀 to the 🌏 EORTC ASPIRE project 🎯harmonise PD-L1 results in GC ➡️ better patients selection for #immunotherapy Lizzy Smyth Raghav Sundar ESMO - Eur. Oncology #EORTC #GITCG #biomarker #ESMOGIoncology #TIP

Adj chemo decisions are complex in stage 2 colon ca 🤔 🚨New analysis of CD3/CD8 TILs in QUASAR trial ✅1st in early CRC RCT 💪stronger prog. effect than ANY routinely measured stage 2 “high risk” feature High v low CD3 Score = 3x 5yr recurrence risk ascopubs.org/doi/abs/10.120…

Esattamente.

Sunitinib for the treatment of patients with advanced pheochromocytoma... sciencedirect.com/science/articl…

Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of organotropism, the important role of the tumor microenvironment and novel biomarkers. Just published in Gastroenterology! Joseph J Zhao gastrojournal.org/article/S0016-…

Finally we can offer novel second-line options to our patients with PDAC and non-oncogene driven BTC AntiTROP2 ADC SAC-TMT Now enrolling Istituto Tumori clinicaltrials.gov/study/NCT06428…

BRICKET Trial: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Pts BRAF V600E Mutated mCRC In Pisa 16 participants PI: Carlotta Antoniotti, MD, PhD Gruppo Oncologico del Nord-Ovest carlottanto interesting MET ctDNA analysis clinicaltrials.gov/study/NCT06578…

The outcomes of dMMR/MSI-H BRAF V600E mutated #mCRC patients treated with BRAFi+EGFRi+/-MEKi after progression to immune checkpoint inhibitors are unveiled in our newly published #EJC paper based on another important 🌍 effort! To know more ⬇️ kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

dMMR mCRC responds so well to ICI you can forget about the primary tumour, right? Not quite!! 🚨Global case series of bowel obstruction despite response to ICI Incl risk factors to look out for doi.org/10.1016/j.esmo… 👏James Platt ESMO Open

esmoopen.com/article/S2059-… Huge thank you to collaborators Chris Williams Jenny Seligmann Damian Tolan James Glasbey 🇪🇺 Sara Lonardi Dominik Paul Modest Filippo Pietrantonio Kai-Keen Shiu Alice Westwood Yorkshire Cancer Research LIMRLeeds